- Home
- / Kiniksa Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Kiniksa Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$23.3
2024-10-29
Market Capitalization
$1.7 B
2024-10-29
Revenue
$677.6 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 10, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 38.5M | 220.2M | 270.3M | 423.2M | 677.6M | |||
| Cost of goods sold | 9.1M | 60.9M | 77.7M | |||||
| Gross profit | 362.3M | 599.9M | ||||||
| Gross profit margin, % | 85.6% | 88.5% | ||||||
| General and administrative expense | 21.6M | 35.0M | 45.3M | 85.9M | 98.0M | 129.4M | 168.0M | 196.3M |
| Operating expense total | 108.2M | 170.0M | 157.4M | 186.1M | 163.4M | 205.5M | 407.9M | 522.7M |
| EBIT | (108.2M) | (170.0M) | (157.4M) | (156.6M) | 9.8M | (25.2M) | (45.6M) | 77.2M |
| EBIT margin, % | 4.4% | -9.3% | -10.8% | 11.4% | ||||
| Interest income | 4.7M | 6.0M | 1.1M | 97.0K | 9.0M | |||
| Pre tax profit | (103.4M) | (163.9M) | (156.2M) | (156.5M) | 11.0M | (16.7M) | (36.2M) | 88.9M |
| Income tax expense | (214.0K) | (2.0M) | 5.2M | 1.4M | (172.3M) | (30.7M) | 7.0M | 29.9M |
| Net Income | (103.2M) | (161.9M) | (161.4M) | (157.9M) | 183.4M | 14.1M | (43.2M) | 59.0M |
| EPS | 2.6 | 0.2 | (0.6) | 0.8 |